The Time Back campaign for cancer care honors oncologists, the emotional burdens they carry, and the work they do to help make more moments possible for people living with cancer.
To learn more visit, https://www.bms.com/healthcare-providers/time-back-campaign-honoring-oncologists-in-cancer-care.htmlThis brochure from Regeneron provides helpful information on advanced CSCC and advanced BCC in patients of color.
Joint initiative to focus on expanding early detection and equitable access to care through lung cancer specific AI workflows on Microsoft’s suite of radiology solutions. View the full press release.
Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program. View the full press release.
Posted on 11/12/2025
A patient and caregiver website to learn more and find resources about each step of the CAR T cell therapy journey. Visit www.explorecelltherapy.com or download the resource below to learn more.
Posted on 11/12/2025
In addition to surgery, with the evolution of new treatment options, surgeons play a role in referral of patients to medical oncologists or the multidisciplinary team. Coordination with the medical oncologist and the entire care team can help facilitate the development of a treatment plan for patients. The resource will review some factors that may be relevant when considering neoadjuvant and adjuvant therapies.
Published on: February 17, 2025 Watch Dr. David Sallman, a leading MDS specialist at the Moffitt Cancer Center, talk about the importance of investigating unexplained anemia.
Posted on 08.12.2024
Too often, women with endometrial cancer (EC) have reported that their symptoms were stigmatized and dismissed. Even though diagnoses and deaths from this type of uterine cancer are on the rise, EC remains under-recognized.
Spot Her® is an initiative to help end the silence around EC and empower all people across generations and cultures to speak up, take action, and spot the potential signs at an early stage—when EC may be more treatable.